Friday, July 15, 2011

Dapagliflozin - FDA Advisory Committee Meeting

FDA raises red flag -
1) Breast Cancer
2) Bladder Cancer
2) Liver toxicity - Once case of HY's Law..
Likely to be difficult for Dapaglflozin.